AMPLIFICATION OF SELF PROCESSING RNA VECTORS IN PLANTS

我们提出了一种大规模生产定制RNA的新方法， 产品使用植物病毒RNA载体。这种节能、低成本 一种环境友好的方法可以产生长的RNA分子 (not可通过化学合成获得）比 替代的体内和体外转录系统。需的RNA 在实验室中插入RNA载体并扩增的片段 在病毒的生物周期中，仅仅几天后， 在受感染的植物中孵化，容易分离为病毒粒子 （其排除RNA降解并且是理想的储存形式）。后 从病毒体外壳蛋白中简单分离嵌合病毒RNA 亚基，所需的RNA片段将被切割出来并分离 与其他病毒RNA分离为此，我们建议写一本小说。 盒设计，其中RNA载体内的所需RNA片段 将由两个潜在的核酶（在体内无活性），这将 不会影响病毒的扩增它们在体外的活化， 嵌合RNA的分离将通过孵育完成 在体内不存在的溶液环境中。 拟定商业应用： RNA是结构生物学和生物医学研究的重要靶标 包括艾滋病毒和流感病毒。它也有潜力在反义 以及核酶治疗、生物技术产品和分子生物学 工具.我们的技术可以提供大量的定制RNA， 比替代方法更昂贵和更有效。我们目前 商业策略是将这项新技术授权给大公司 例如生物资源技术公司。

We propose a novel approach to large-scale production of custom RNA products using plant viral RNA vectors. This energy efficient, low cost and environmentally friendly method would generate long RNA molecules (not available through chemical synthesis) less expensively than alternative in vivo and in vitro transcription systems. the desired RNA fragment inserted in the laboratory into the RNA vector and amplified through the viral biological cycles could then, after only a few days' incubation in infected plants, be easily isolated as virion particles (which preclude RNA degradation and are an ideal storage form). after simple separation of chimeric viral RNA from the virion coat protein subunits, the desired RNA fragment would be cleaved out and separated from the rest of the viral RNA. For this purpose we suggest a novel cassette design where the desired RNA fragment within the RNA vector would be flanked by two latent ribozymes (inactive in vivo), which will not compromise the virus amplification. Their activation in vitro after isolation of the chimeric RNA will be accomplished through incubation in a solution environment not presented in vivo. PROPOSED COMMERCIAL APPLICATION: RNA is an important target for structural biology and biomedical studies including HIV and influenza viruses. It also has potential in antisense and ribozyme therapeutics, biotechnology products and molecular biology tools. Our technology would provide large amounts of custom RNAs less expensively and more efficiently than alternative methods. Our current business strategy is to license this new technology to larger companies such as Biosource Technologies.